High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory marginal zone non-Hodgkin' s lymphoma

VernacularTitle:大剂量化疗联合自体造血干细胞移植治疗复发、难治性边缘区非霍奇金淋巴瘤疗效观察
Author: Xiangrui MENG ; Huaqing WANG ; Xiuzhen CUI
Publication Type:Journal Article
Keywords: Hematopoietic stem cell transplantation; Lymphoma,B-cell,marginal zone; Relapsed; Refractory
From: Journal of Leukemia & Lymphoma 2012;21(10):595-597
CountryChina
Language:Chinese
Abstract: Objective To evaluate the role of high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory marginal zone lymphomas. Methods The transplant database was reviewed retrospectively from Tianjin Medical University Cancer Hospital identified 12 patients who underwent high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation. Results Among the twelve patients who underwent autologous hematopoietic stem cell transplantation, the median duration of progression-free survival (PFS) was 104 months and the median duration overall survival (OS) was 117 months; 6 patients were still alive with disease-free. Conclusion High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation is feasible to patients with relapsed/refractory marginal zone lymphomas, particularly to those insensitive to rituximabincluded combined chemotherapy.